PainReform Ltd. (PRFX) Financial Ratios
8 years of historical data (2017–2024) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.47
↓-77% vs avg
5yr avg: 2.03
30Y Low0.5·High4.2
ROE
↓
-321.9%
↑-168% vs avg
5yr avg: -120.0%
30Y Low-322%·High-42%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PRFX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
PainReform Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $861734 | $8M | $4M | $6M | $16M | $65M | — | — | — |
| Enterprise Value | $-3354266 | $3M | $-3440615 | $1M | $-224284 | $50M | — | — | — |
| P/E Ratio → | -0.06 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 64.00 | — | — | — | — | — |
| P/B Ratio | 0.47 | 4.17 | 0.62 | 0.50 | 0.90 | 3.94 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PRFX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 16.37 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
PRFX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -321.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 82.6% | — | — | — | — | — |
| Operating Margin | — | — | — | -10312.8% | — | — | — | — | — |
| Net Profit Margin | — | — | — | -10223.3% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -321.9% | -321.9% | -102.3% | -60.4% | -41.8% | -73.7% | — | — | — |
| ROA | -201.8% | -201.8% | -84.0% | -56.0% | -39.3% | -42.7% | -292.4% | -561.4% | -976.6% |
| ROIC | — | — | -231.0% | -157.1% | -434.6% | -453.3% | — | -1630.4% | — |
| ROCE | -305.6% | -305.6% | -102.0% | -60.0% | -41.0% | -28.6% | — | -704.2% | -1113.9% |
PRFX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $4M exceeds total debt of $45000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.01 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -2.31 | -1.10 | -0.37 | -0.91 | -0.94 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1048.07 | -1048.07 | -24.96 | -145.39 | -720.80 | -1.69 | -1.27 | -1.54 | — |
Net cash position: cash ($4M) exceeds total debt ($45000)
PRFX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.81x means PainReform Ltd. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 11.55x to 1.81x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.81 | 1.81 | 4.07 | 11.55 | 25.13 | 18.51 | 0.15 | 4.44 | 1.58 |
| Quick Ratio | 1.81 | 1.81 | 4.07 | 4.19 | 25.13 | 16.39 | 0.15 | 4.44 | 1.58 |
| Cash Ratio | 1.74 | 1.74 | 3.33 | 3.85 | 21.85 | 16.31 | 0.15 | 2.22 | 1.39 |
| Asset Turnover | — | — | — | 0.01 | — | — | — | — | — |
| Inventory Turnover | 0.00 | — | — | 0.00 | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 233.43 | — | — | — | — | — |
PRFX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
PainReform Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $453544 | $54538 | $44421 | $40884 | $48801 | $38783 | $57656 | $57656 |
Peer Comparison
Compare PRFX with 9 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PRFXYou | $861734 | -0.1 | — | — | — | — | -321.9% | — | — |
 PCRX | $930M | 147.8 | 9.9 | 6.8 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 ACRS | $586M | -9.2 | — | — | 73.3% | -975.9% | -50.2% | -53.5% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 XTLB | $293767 | -0.3 | — | — | 0.7% | -481.6% | -26.8% | -54.1% | — |
 BHC | $2B | 13.3 | 6.4 | 2.1 | 60.9% | 21.3% | 588.2% | 8.2% | 6.1 |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 DARE | $25M | -6.1 | — | 5.3 | -146110.2% | -239692.2% | — | — | — |
 COLL | $1B | 22.7 | 4.8 | 3.9 | 59.3% | 24.0% | 23.7% | 14.0% | 2.3 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See PRFX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRFX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRFX vs PCRX
Side-by-side business, growth, and profitability comparison vs Pacira BioSciences, Inc..
Start ComparisonPRFX — Frequently Asked Questions
Quick answers to the most common questions about buying PRFX stock.
What is PainReform Ltd.'s P/E ratio?
PainReform Ltd.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is PainReform Ltd.'s ROE?
PainReform Ltd.'s return on equity (ROE) is -321.9%. The historical average is -120.0%.
Is PRFX stock overvalued?
Based on historical data, PainReform Ltd. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.